Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, speaks on misconceptions regarding Fabry disease and opportunities for improvement in care.
There are several misconceptions regarding Fabry disease, including inheritance, initiation of treatment, and its impact on women, said Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center.
Transcript
Can you discuss common misconceptions regarding Fabry disease and any potential for improvement in care?
There are a number of misconceptions. Even among the people who have Fabry disease, a lot of people have this idea that we treat disease when it becomes a problem. So, there are lots of people who say, "I will come in when the disease gets to the point that it's impacting my life in a way that I know needs intervention and then I will seek help."
That's just not an effective strategy at this time, because as I've mentioned, the damage is irreversible. When cells are damaged in Fabry disease they're replaced by fibroblasts or by fibrous tissue—not by functional kidney cells, heart cells, or neurons—which means the damage that has already been done is not going to get better, even if we have successful treatment after you've had damage done to your body.
So, one of the misconceptions is that you should wait until you absolutely need treatment. And interestingly, that sort0-of concept is incorporated in the treatment strategies promoted in some parts of the world where they say until you have clear, functional damage to your kidneys or heart, we don't want to treat you.
There are also misconceptions about inheritance. Fabry disease is an X-linked disorder, and there's still a lot of people who think, well, if it's an X-linked disorder, it shouldn't affect women or that most women will only have mild disease. But in fact, in the studies that have been done, where they specifically sought out women based usually on family history, who were obligated to have inherited a mutation in the gene, people who have changes in the gene that are associated with classical Fabry disease, the women in that group, about three-quarters of them will develop problems related to Fabry disease—and that isn't just mild discomfort.
It's progressive kidney disease, it's life-threatening heart disease, it's a multiple-fold increased risk in stroke. Women untreated lose about 15 years of life expectancy, and they have a significant detriment in quality of life. So, the idea that women are not really a priority in treatment is unsupported by the data and, in fact, is refuted by the studies that have been done.
There's still a lot of people who think that the treatment doesn't make a big difference, but I think that that is incorrect. The treatment prolongs life and can improve quality of life if it's done optimally.
So, misconceptions: One is that we can wait until the disease is advanced. I think we need to look for Fabry disease early in life and try to treat before people notice that there's a problem and prevent the disease from progressing or at least minimize the progression. And the misconceptions that women will often not have disease or not have severe disease are also important. Then the idea that the treatments don't make a difference, I mean they do make a difference. We need to do things about Fabry disease.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More